MEDS trxade healt Inc. il futuro..

kada1992

Nuovo Utente
Registrato
12/7/15
Messaggi
1.954
Punti reazioni
102
TRxADE HEALTH, INC. to Report Second Quarter 2022 Financial Results on Monday, July 25th at 5:00 p.m. Eastern Time
 

kada1992

Nuovo Utente
Registrato
12/7/15
Messaggi
1.954
Punti reazioni
102
TRxADE Health Inc reports results for the quarter ended in June - Earnings Summary

* TRxADE Health Inc reported a quarterly adjusted loss of 13 cents​​ per share for the quarter ended in June. The mean expectation of three analysts for the quarter was for a loss of 8 cents per share.

* Revenue rose 72.7% to $3.28 million from a year ago; analysts expected $2.93 million.

* TRxADE Health Inc's reported EPS for the quarter was a loss of 13 cents​.

* The mean earnings estimate of analysts had risen by about 20% in the last three months.​
* In the last 30 days there have been no earnings estimate revisions by analysts covering the company.

* TRxADE Health Inc shares had risen by 3.1% this quarter and lost 29.2% so far this year.

* The company reported a quarterly loss of $1.08 million.

* Wall Street's median 12-month price target for TRxADE Health Inc is $4.00
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

This summary was machine generated from Refinitiv data July 25 at 10:41 p.m. ​All figures in US dollars unless otherwise stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2022 -0.08 -0.13 Missed
Mar. 31 2022 -0.11 -0.12 Missed
Dec. 31 2021 -0.15 -0.10 Beat
Sep. 30 2021 -0.13 -0.16 Missed

By Fineco
 

_Blizzard_

Nuovo Utente
Registrato
29/8/18
Messaggi
740
Punti reazioni
28
Presente e incastrato anche io... fatto ultima mediata a 1.30$ e PMC abbastanza alto... se non fallisce o delistano prima, staremo a vedere che succede
Intanto vediamo a settembre che rispondono rispetto alla compliance di quotazione
 

beppofinanza

Nuovo Utente
Registrato
7/1/21
Messaggi
623
Punti reazioni
15
Presente e incastrato anche io... fatto ultima mediata a 1.30$ e PMC abbastanza alto... se non fallisce o delistano prima, staremo a vedere che succede
Intanto vediamo a settembre che rispondono rispetto alla compliance di quotazione
Speriamo
 

kada1992

Nuovo Utente
Registrato
12/7/15
Messaggi
1.954
Punti reazioni
102
BUZZ-TRxADE Health scraps planned equity offering, shares down
** TRxADE Health Inc's shares down 9.1% at $1.20 premarket after drug procurement marketplace pulls planned equity raise
** Co says current market conditions not conducive for an offering on terms in best interests of its stockholders (NEWS)

** MEDS dropped >25% after hours on Tues when co commenced offering without disclosing deal size (See prospectus filing https://www.sec.gov/Archives/edgar/data/1382574/000149315222023831/form424b5.htm)
** Shares have lost 44% in 2022 and 72% over past year through Tues close
** Co has ~8.18 mln shares outstanding and ~3.34 mln of public float, per Refinitiv data
** On Jul 25, co reported Q2 rev growth of 73% yr/yr to $3.3 mln and net loss of $1.1 mln (NEWS)
 

kada1992

Nuovo Utente
Registrato
12/7/15
Messaggi
1.954
Punti reazioni
102
TAMPA, FL, Aug. 30, 2022 (GLOBE NEWSWIRE) -- TRxADE HEALTH, INC. (NASDAQ: MEDS)(“TRxADE” or the “Company”) an integrated drug procurement, delivery, and healthcare marketplace platform that connects buyers and sellers, today announced the launch of the Trxade Prime Plus program via its pharmaceutical wholesale business subsidiary, Integra Pharma Solutions LLC (d/b/a TRxADE Prime), to allow its member pharmacies better access to over 20,000 pharmaceutical products available for next day delivery without them incurring any additional shipping costs.

The Company, which distributes generic and brand medications directly in 34 states through its warehouse operations, will now offer pharmacies improved supply chain logistics. The new program offering signifies TRxADE’s commitment to its network of independent pharmacies by optimizing pharmaceutical distribution while simultaneously lowering product costs via its proprietary technology platform.

Jariel (Jay) Morales, Executive Vice President of Operations for TRxADE states, “We are excited about the launch of TRxADE Prime Plus and feel confident that the offering will position our pharmacy buyers for success as delivery timelines can now be reduced significantly on the Trxade Prime program ensuring we meet our customers’ needs of on demand inventory with as late as an 8 PM cutoff for next day delivery. Pharmacy partners that wish to join TRxADE Prime Plus will now be able to access even lower pricing on pharmaceuticals negotiated by TRxADE with national suppliers and the assurance and commitment of quality service without legacy chargeback or surcharge costs. We expect that this new program offering will improve gross revenues for TRxADE as there will be less deterrents for pharmacy buyers, as we continue to make it easier for our members to maximize their savings and thrive in today’s market.”

Dr. Shafaat Pirani, PharmD, BCGP, Chief Clinical and Compliance Officer for TRxADE added, “We believe that the Trxade Prime Plus program is a vital step in maintaining TRxADE’s position as one of the leaders in pharmaceutical marketplace supply chain distribution for pharmacies and medical offices by providing access to lower priced pharmaceuticals, through an efficient AI-driven platform, with a single access point designed to drive compliance.

We have found that independent pharmacies want to make a positive impact on patient outcomes and we believe that starts with their patients receiving medically necessary prescriptions in a timely manner.”

“We are pleased to announce our new TRxADE Prime Plus program for our independent pharmacies, as it will improve pharmacy turnaround time on prescription procurement and dispensing. At TRxADE, we value our loyal pharmacy buyer and view the relationship as a partnership. We listen to their feedback and pain points and work to develop innovative solutions that put our independent pharmacies in a position to succeed in an everchanging competitive healthcare landscape,” said Suren Ajjarapu, Chairman and Chief Executive Officer of TRxADE.
 

kada1992

Nuovo Utente
Registrato
12/7/15
Messaggi
1.954
Punti reazioni
102
TRxADE Health Inc reports results for the quarter ended in September - Earnings Summary
* TRxADE Health Inc reported a quarterly adjusted loss of 6 cents​​ per share for the quarter ended in September. The mean expectation of three analysts for the quarter was for a loss of 12 cents per share.

* Revenue fell 5.9% to $2.40 million from a year ago; analysts expected $3.30 million.

* TRxADE Health Inc's reported EPS for the quarter was a loss of 6 cents​.

* The mean earnings estimate of analysts had risen by about 4% in the last three months.​
* In the last 30 days there have been no negative revisions of earnings estimates
* TRxADE Health Inc shares had fallen by 25.7% this quarter and lost 64.4% so far this year.

* The company reported a quarterly loss of $528 thousand.

* Wall Street's median 12-month price target for TRxADE Health Inc is $3.00
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

This summary was machine generated from Refinitiv data November 7 at 10:49 p.m. ​All figures in US dollars unless otherwise stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2022 -0.12 -0.06 Beat
Jun. 30 2022 -0.08 -0.13 Missed
Mar. 31 2022 -0.11 -0.12 Missed
Dec. 31 2021 -0.15 -0.10 Beat
 

kada1992

Nuovo Utente
Registrato
12/7/15
Messaggi
1.954
Punti reazioni
102

Bonum Health(TM), LLC (a TRxADE HEALTH Company) Reaffirms its Commitment to Independent Pharmacies and Group Purchasing Organizations (GPOs) with its Novel Telemedicine Services Model​

(NASDAQ:MEDS)("TRxADE" or the "Company") an integrated drug procurement, delivery, and healthcare platform, today announced that Bonum Health, a Digital Healthcare business subsidiary, has signed a preferred telemedicine services agreement with an independent group purchasing organization (GPO) which will provide deep discounts to access Bonum Health's service platform for 100+ pharmacies and their patient's in the northeastern part of the United States.

The Company, which offers nationwide telemedicine services in all 50 states for humans and select states for pets, has grown its presence with independent pharmacies by promoting telemedicine services to its patient base. Dr. Shafaat Pirani, PharmD, BCGP, Chief Clinical and Compliance Officer for TRxADE states, "We have seen an increase in interest among the independent pharmacy community who are looking to diversify their service offerings to patients by providing affordable access to telehealth solutions for the growing uninsured and under-insured patient population. In most states, pharmacists are not recognized as Providers with prescriptive authority, and must therefore submit medication recommendations to the prescriber, which often leads to delays in therapy which may lead to adverse outcomes for patients. The ability to connect a patient with a telemedicine provider using our mobile application, for a simple medication refill or to prescribe an acute course of antibiotics or steroids for an infection, is the type of convenience we believe patients are seeking in today's digital environment."

Dr. Pirani went on to further discuss that, "We have seen that independent pharmacies that do not provide in-house clinical services are losing patients to the enterprise pharmacy chains, like CVS Health's Health Hub Model or via Walgreen's Village MD Clinic Partnership, where patients can walk in and quickly see a provider in person. We are working to provide a solution to this problem for the nation's independent pharmacies, by strategically working with and recruiting GPOs to promote Bonum Health's service offering, while also providing deeper discounts to patients based on market share. Our strategy is focused on garnering strategic business-to-business (B2B) opportunities like this, and we believe we have several opportunities in the immediate pipeline."

Suren Ajjarapu, Chairman and Chief Executive Officer of TRxADE added, "We are pleased to see such a positive response from the independent pharmacy community. Our mission at TRxADE has been to empower the independent pharmacy market by providing cost savings on pharmaceutical products, and we see an opportunity to help boost foot traffic and prescriptions to our network of pharmacies." Mr. Ajjarapu added, "We have operated with success in the business-to-business (B2B) markets and we believe that partnering with independent GPOs and buying groups will continue to enhance our position and provide value to our eco-system of pharmacies."

About TRxADE HEALTH, INC.

TRxADE HEALTH (NASDAQ:MEDS) is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey, and patient engagement in the U.S. The Company operates the TRxADE drug procurement marketplace serving a total of 14,100+ members nationwide, fostering price transparency, and under the Bonum Health brand, offering patient-centric telehealth services and tele vet services (Accessible and Affordable Insurance-Free Telehealth | Bonum Health). For information on TRxADE, please visit the Company's IR website at investors.trxadehealth.com (Homepage - Trxade Group).

Forward-Looking Statements This press release may contain forward-looking statements, including information about management's view of TRxADE's future expectations, plans, and prospects, within the meaning of the federal securities laws, including the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "will," "would" and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event, or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of TRxADE, its divisions, and concepts to be materially different from those expressed or implied in such statements. These risks include risks relating to agreements with third parties; including Wakefern Food Corp., Coborn's, Galt Pharmaceuticals, and others; our ability to raise funding in the future, as and if needed, and the availability and terms of such funding, including potential dilution caused thereby; TRxADE's ability to continue as a going concern; the planned benefits, expected users of and projected revenues of our venture with Exchange Health and other third parties; amounts we owe and may owe to Exchange Health in connection with the arrangement with Exchange Health; security interests under certain of our credit arrangements; the fact that we are exploring strategic alternatives for our B2C subsidiaries, including Bonum Health, Inc.; our ability to maintain the listing of our common stock on the Nasdaq Capital Market, including our current non-compliance with the continued listing standards of the Nasdaq Capital Market; risks associated with TRxADE's operations not being profitable; the commercial viability of new business lines, applications, products and technologies, and the costs of such items; the adoption of the Company's product offerings; claims relating to alleged violations of intellectual property rights of others; our ability to monetize our technological solutions; technical problems with our websites, apps, and products; risks relating to implementing our acquisition strategies; challenges to the pharmaceutical supply chain posted by the COVID-19 pandemic and related matters; our ability to manage our growth; negative effects on our operations associated with the opioid pain medication health crisis; regulatory and licensing requirement risks; risks related to changes in the U.S. healthcare environment; the status of our information systems, facilities and distribution networks; risks associated with the operations of our more established competitors; regulatory changes; new competitors which may have more resources than we do; increases in direct to consumer sales of drugs; healthcare fraud; COVID-19, governmental responses thereto, economic downturns and increased inflation and possible recessions caused thereby; changes in laws or regulations relating to our operations; privacy laws; system errors; dependence on current management; our growth strategy; dilution which may be caused by future offerings; increased inflation and interest rates, including the increased costs of raising funding as a result thereof; supply chain issues caused by among other things, recessions and global conflicts; and others that are included from time to time in filings made by TRxADE with the Securities and Exchange Commission, including, but not limited to, in the "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors" sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which it has filed, and files from time to time, with the U.S. Securities and Exchange Commission (SEC), and more particularly in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 and our Annual Report on Form 10-K for the year ended December 31, 2021. These reports are available at www.sec.gov. Other unknown or unpredictable factors also could have material adverse effects on TRxADE's future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. TRxADE cannot guarantee future results, levels of activity, performance, or achievements.

Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions, or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws.

If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.